162 related articles for article (PubMed ID: 24376241)
1. Childhood acute lymphoblastic leukemia in Nicaragua: long-term results in the context of an international cooperative program.
Pacheco C; Lucchini G; Valsecchi MG; Malta A; Conter V; Flores A; Biondi A; Tognoni G; Arguello M; Cavalli F; Silvestri D; Lacayo FB; Masera G
Pediatr Blood Cancer; 2014 May; 61(5):827-32. PubMed ID: 24376241
[TBL] [Abstract][Full Text] [Related]
2. Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience.
Navarrete M; Rossi E; Brivio E; Carrillo JM; Bonilla M; Vasquez R; Peña A; Fu L; Martinez R; Espinoza CM; Lacayo LF; Rodriguez H; Batista R; Barr R; Howard SC; Ribeiro RC; Masera G; Biondi A; Conter V; Valsecchi MG
Pediatr Blood Cancer; 2014 May; 61(5):803-9. PubMed ID: 24376115
[TBL] [Abstract][Full Text] [Related]
3. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Mora J; Filippa DA; Qin J; Wollner N
Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853
[TBL] [Abstract][Full Text] [Related]
4. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
5. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
[TBL] [Abstract][Full Text] [Related]
6. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
[TBL] [Abstract][Full Text] [Related]
8. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
9. Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience.
Hazar V; Karasu GT; Uygun V; Akcan M; Küpesiz A; Yesilipek A
J Pediatr Hematol Oncol; 2010 Nov; 32(8):e317-22. PubMed ID: 20930649
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
11. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
[TBL] [Abstract][Full Text] [Related]
12. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
Veerman AJ; Hählen K; Kamps WA; Van Leeuwen EF; De Vaan GA; Solbu G; Suciu S; Van Wering ER; Van der Does-Van der Berg A
J Clin Oncol; 1996 Mar; 14(3):911-8. PubMed ID: 8622039
[TBL] [Abstract][Full Text] [Related]
13. [Long-term follow-up of 2 therapeutic programs for the treatment of high-risk childhood acute lymphoblastic leukemia. Experience at the 20 de Noviembre National Medical Center].
de Diego-Floreschapa J; López-Hernández M; Borbolla-Escoboza JR; Trueba-Christy E; Carrillo-Rosales T; González-Avante M
Gac Med Mex; 1999; 135(3):253-8. PubMed ID: 10425822
[TBL] [Abstract][Full Text] [Related]
14. [Results of the CCLSG high risk ALL 874 protocol in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group].
Kawai S; Fujimoto T; Zha Z; Asami K; Oka T; Kaneko Y; Takaue Y; Ninomiya T; Nishikawa K; Tsuchiya T
Rinsho Ketsueki; 1993 Feb; 34(2):128-36. PubMed ID: 8492409
[TBL] [Abstract][Full Text] [Related]
15. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
16. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
17. [Clinical trial of protocol-AL851 for children with high-risk acute lymphoblastic leukemia. Kyushu Yamaguchi Children's Cancer Study Group (KYCCSG)].
Matsuzaki A; Ishii E; Ueda K; Yanai F; Nibu K; Take H; Koga H; Miyazaki S; Inoue T; Miyake K
Rinsho Ketsueki; 1994 Sep; 35(9):862-70. PubMed ID: 7967055
[TBL] [Abstract][Full Text] [Related]
18. Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador.
Bonilla M; Moreno N; Marina N; deReyes G; Shurtleff SA; Downing JR; Behm FG; Harrison PL; Ribeiro RC; Peña O; Crist WM; Antillon FG
J Pediatr Hematol Oncol; 2000; 22(6):495-501. PubMed ID: 11132215
[TBL] [Abstract][Full Text] [Related]
19. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
[TBL] [Abstract][Full Text] [Related]
20. [Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].
Kwiecińska K; Balwierz W; Moryl-Bujakowska A; Wachowiak J; Derwich K; Matysiak M; Pawelec K; Chybicka A; Dobaczewski G; Kowalczyk JR; Wiśniewska-Slusarz H; Sońta-Jakimczyk D; Szczepański T; Tomaszewska R; Wysocki M; Styczyński J; Balcerska A; Płoszyńska A
Przegl Lek; 2010; 67(6):350-4. PubMed ID: 21344760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
